Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer
- 318 Downloads
To compare plasma lysophosphatidic acid (LPA) levels in ovarian cancer patients in women with benign ovarian tumors and in women with no ovarian pathology. We correlated clinico-pathological parameters with plasma LPA levels. Capillary electrophoresis with indirect ultraviolet detection was used to analyze the plasma LPA levels of 159 patients (81 patients with ovarian cancer, 27 women without ovarian or uterine pathologies, and 51 patients with benign ovarian tumors) during a 5-year period. Patients with ovarian cancer had a significantly higher plasma LPA level (n = 81; median (med), 11.53 μmol/l; range, 1.78–43.21 μmol/l) compared with controls with no ovarian pathology (n = 27; med, 1.86 μmol/l; range, 0.94–9.73 μmol/l), and patients with benign ovarian tumor (n = 51; med, 6.17 μmol/l; range, 1.12–25.23 μmol/l; P < 0.001). We found that plasma LPA levels were associated with the International Federation of Gynecology and Obstetrics stage. The histological subtype and grade of ovarian cancer did not influence the plasma LPA levels in this study. The plasma LPA level can be a useful marker for ovarian cancer, particularly in the early stages of the disease.
KeywordsOvarian carcinoma Lysophosphatidic acid Marker Diagnostics
This project was supported by the Ministry of Health Grant Agency, No. 97373.
Conflicts of interest
The authors declare that there are no conflicts of interest.
- 4.Fang X, Schummer M, Mao M, et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta. 2002;23:57–64.Google Scholar
- 6.Xiao YJ, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J, et al. Electrospray ionization spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant versus nonmalignant ascitic fluids. Anal Biochem. 2001;290:302–13.CrossRefPubMedGoogle Scholar
- 7.Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N, et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst. 2006;93:762–8.Google Scholar
- 12.Ozols RF, Rubin SC, Thomas G, Robboy S. Asdf. In: Hoskins WJ, Perez CA, Zouny RC, editors. Epithelial ovarian cancer. Principles and practisse of gynecologic oncology. Philadelphia: Lippincott-Raven; 1997. p. 958.Google Scholar
- 13.WHO. WHO Handbook for reporting results of cancer treatment. Geneva: WHO; 1979.Google Scholar
- 14.Sutphen R, Xu Y, Wilbanks D, Fiorica J, Grendys Jr EC, La Polla JP, et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidem. 2004;13:1185–91.Google Scholar
- 20.So J, Wang F, Navari J, Schreher J, Fishman DA. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynec Oncol. 2005;97:870–8.Google Scholar